Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination.

By Yi-Nan Zhang, Wilson Poon, A. J. Tavares, I. McGilvray, Warren C. W. Chan. Journal of Controlled Release, 2016

1,160 citations recorded by the source corpus.

30-99% of administered nanoparticles will accumulate and sequester in the liver after administration into the body. This results in reduced delivery to the targeted diseased tissue and potentially leads to increased toxicity at the hepatic cellular level. This review article focuses on the inter- and intra-cellular interaction between nanoparticles and hepatic cells, the elimination mechanism of nanoparticles through the hepatobiliary system, and current strategies to manipulate liver sequestration. The ability to solve the "nanoparticle-liver" interaction is critical to the clinical translation of nanotechnology for diagnosing and treating cancer, diabetes, cardiovascular disorders, and other diseases.

Subfields: Biomaterials, Biomedical Engineering, Hepatology

View Paper: https://www.semanticscholar.org/paper/503d4d9426fcef5ebe84f7daf4165191a7678290

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. Handan Acar
2. Stefan Wilhelm
3. Nathan D. Donahue

Citations in the corpus

• Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. (2019, background): “Intravenously administered nanoparticles typically undergo rapid opsonization upon contact with blood [65,66].”